Five key benefits include:Unprecedented Weight Loss: In clinical trials (such as the Phase 3 TRIUMPH studies), patients achieved average weight reductions of up to 28% to 30% of their starting body weight over 80 weeks, rivaling the efficacy of bariatric surgery.Increased Energy Expenditure: Unlike older therapies that solely limit calorie intake, activating the glucagon receptor stimulates the body to burn more calories at rest and break down stored fat for fuel.Enhanced Liver Health: Retatrutide demonstrates dramatic reductions in harmful hepatic fat (by up to 86%), showing great promise for managing conditions like non-alcoholic fatty liver disease (NAFLD) and MASH.Stronger Appetite Control: By mimicking natural hormones, it drastically reduces "food noise," increases early satiety, and helps prevent dips in blood sugar, making consistent, healthy eating much easier to maintain.Improved Metabolic and Cardiovascular Markers: The therapy significantly improves insulin sensitivity (helping reverse prediabetes) and reduces visceral fat, which subsequently leads to positive changes in lipid profiles and blood pressure.
For RESEARCH PURPOSES ONLY